Intensity Therapeutics, Inc. (INTS) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Intensity Therapeutics, Inc. (INTS) trades at $4.88 with AI Score 27/100 (Grade F). Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer drugs for solid tumors. Market cap: $13.2M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for INTS: INTS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INTS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INTS: 1/3 scored disciplines lean bearish. Dominant signal: Valuation weak.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Intensity Therapeutics, Inc. (INTS) Healthcare & Pipeline Overview
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of novel cancer therapies targeting solid tumors. Their lead candidate, INT230-6, is undergoing Phase 2 clinical trials and is being evaluated in combination with established therapies through collaborations with major pharmaceutical companies, positioning them in a competitive oncology market.
What Is the Investment Thesis for INTS?
Intensity Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's value is primarily tied to the clinical success of INT230-6, currently in Phase 2 trials. Positive data from these trials, expected to be released incrementally over the next 12-24 months, could serve as a significant catalyst, potentially leading to increased investor interest and partnership opportunities. The collaborations with Merck and Bristol-Myers Squibb provide validation of the INT230-6 platform and offer potential revenue streams through milestone payments and royalties. However, the company's limited financial resources and reliance on clinical trial outcomes pose substantial risks. Failure to demonstrate efficacy or safety in ongoing trials would severely impact the company's valuation. The company's market capitalization of $13.2M reflects the speculative nature of this investment.
Based on FMP financials and quantitative analysis
INTS Key Highlights
INT230-6 is in Phase 2 clinical trials targeting a range of refractory solid tumors, indicating progress in clinical development.
- Collaboration agreements with Merck and Bristol-Myers Squibb validate the potential of INT230-6 and provide access to established therapies like Keytruda and Yervoy.
- Focus on intratumoral injection of INT230-6 represents a novel approach to cancer treatment, potentially offering advantages over systemic therapies.
- Partnership with Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research supports further research and development of INT230-6 in breast cancer.
- The company's small size (5 employees) allows for focused research efforts but also presents operational risks.
Who Are INTS's Competitors?
INTS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| MRK Merck & Co., Inc. | $152.22 | +12.61% | $376B | 75 |
| BMY Bristol-Myers Squibb Company | $65.47 | -3.17% | $134B | 90 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INTS's Key Strengths?
Novel intratumoral drug delivery technology.
- Collaboration agreements with major pharmaceutical companies.
- Phase 2 clinical trials underway for INT230-6.
- Focus on difficult-to-treat solid tumors.
What Are INTS's Weaknesses?
Limited financial resources.
- Small team size.
- Reliance on clinical trial success.
- High risk of clinical trial failure.
What Could Drive INTS Stock Higher?
INTS catalyst: Data readouts from ongoing Phase 2 clinical trials of INT230-6 in various solid tumors (next 6-18 months).
- Potential initiation of new clinical trials for INT230-6 in additional cancer types (next 12-24 months).
- Progress in collaboration agreements with Merck and Bristol-Myers Squibb.
- Advancements in research and development of next-generation intratumoral therapies.
What Are the Key Risks for INTS?
Financial-distress signal — its Altman Z-Score of -9.52 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for INT230-6.
- Regulatory delays or rejection of INT230-6.
- Competition from other cancer drug developers.
- Limited financial resources and reliance on external funding.
- Patent expiration and loss of exclusivity for INT230-6.
What Are the Growth Opportunities for INTS?
- Expansion of INT230-6 Clinical Trials: Intensity Therapeutics has the opportunity to expand the clinical trials for INT230-6 to include additional cancer types and patient populations. This would broaden the potential market for the drug and increase its commercial value. The market for cancer therapeutics is projected to reach $250 billion by 2028, providing a significant opportunity for growth. Timeline: Ongoing, with new trials potentially initiated in the next 12-24 months.
- Securing Additional Partnerships: The company can pursue additional partnerships with pharmaceutical companies to further develop and commercialize INT230-6. These partnerships could provide additional funding, resources, and expertise. The pharmaceutical industry is actively seeking innovative cancer therapies, creating a favorable environment for partnerships. Timeline: Ongoing, with potential for new partnerships in the next 12-36 months.
- Development of Next-Generation Intratumoral Therapies: Intensity Therapeutics can leverage its expertise in intratumoral drug delivery to develop next-generation therapies with improved efficacy and safety profiles. This would strengthen its competitive position and create new revenue streams. The market for targeted drug delivery systems is growing rapidly, driven by the need for more effective and less toxic cancer treatments. Timeline: Long-term, with research and development efforts ongoing.
- Out-licensing or Acquisition: The company could out-license or be acquired by a larger pharmaceutical company. This would provide a significant return on investment for shareholders. The pharmaceutical industry is actively consolidating, with larger companies acquiring smaller biotech firms with promising drug candidates. Timeline: Uncertain, but potential for an acquisition in the next 3-5 years.
- Positive Clinical Trial Data Readouts: Upcoming data readouts from ongoing Phase 2 clinical trials represent a significant growth opportunity. Positive results could lead to increased investor confidence, higher stock valuation, and accelerated development timelines. The success of INT230-6 hinges on demonstrating efficacy and safety in these trials. Timeline: Near-term, with data readouts expected in the next 6-18 months.
What Are INTS's Competitive Advantages?
- Proprietary INT230-6 formulation and intratumoral delivery technology.
- Established collaborations with major pharmaceutical companies like Merck and Bristol-Myers Squibb.
- Patent protection for INT230-6 and related technologies.
- Expertise in intratumoral drug delivery and cancer biology.
What Does INTS Do?
Intensity Therapeutics, Inc., founded in 2012 and headquartered in Westport, Connecticut, is a clinical-stage biotechnology company dedicated to discovering, developing, and commercializing innovative cancer drugs for the treatment of solid tumors. The company's primary focus is on its lead product candidate, INT230-6, a novel drug designed for direct intratumoral injection. INT230-6 is currently in Phase 2 clinical trials, targeting a range of refractory solid tumors, including pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. This therapeutic approach aims to induce tumor cell death and stimulate an anti-tumor immune response. Intensity Therapeutics has established strategic collaboration agreements with Merck Sharpe & Dohme Corp. to evaluate INT230-6 in combination with Keytruda, focusing on advanced pancreatic, colon, squamous cell, and bile duct malignancies. Additionally, they are collaborating with Bristol-Myers Squibb Company to assess the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers. Further research is being conducted in partnership with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company's business model centers on advancing INT230-6 through clinical trials and securing partnerships to broaden its therapeutic applications and market reach.
What Products and Services Does INTS Offer?
- Develop cancer drugs to treat solid tumors.
- Focus on intratumoral injection as a method of drug delivery.
- Conduct Phase 2 clinical trials for INT230-6.
- Collaborate with pharmaceutical companies to evaluate INT230-6 in combination with other therapies.
- Partner with research institutions to study INT230-6 in various cancer types.
- Engage in the discovery of new cancer drug candidates.
How Does INTS Make Money?
- Develop and patent novel cancer therapeutics.
- Conduct clinical trials to demonstrate safety and efficacy.
- Out-license or partner with larger pharmaceutical companies for commercialization.
- Generate revenue through milestone payments, royalties, and potential future product sales.
What Industry Does INTS Operate In?
Intensity Therapeutics operates within the highly competitive biotechnology industry, specifically focusing on oncology. The market for cancer therapeutics is substantial and growing, driven by an aging population and advancements in cancer research. The company's approach of direct intratumoral injection of INT230-6 differentiates it from companies developing systemic therapies. Key trends in the industry include the rise of immunotherapy, personalized medicine, and combination therapies. Intensity Therapeutics' collaborations with Merck and Bristol-Myers Squibb align with the trend of combining novel agents with established immunotherapies to enhance efficacy. The competitive landscape includes major pharmaceutical companies and numerous smaller biotech firms developing cancer drugs.
Who Are INTS's Key Customers?
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Cancer patients with refractory solid tumors who may benefit from INT230-6.
- Research institutions interested in collaborating on cancer research projects.
Company Profile
Intensity Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Shelton, US. The company is led by CEO Lewis H. Bender. INTS has traded publicly since 2023.
How Intensity Therapeutics, Inc. Is Valued
Intensity Therapeutics, Inc. carries a market capitalization of $13.2M, placing it in the micro-cap category. Relative to its peer group, INTS's quantitative score of 27/100 is below the peer average of 79/100.
Key Financial Metrics
Return on assets is -87.0%, showing how much profit it generates from its asset base. A current ratio of 4.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Intensity Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.52 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Intensity Therapeutics, Inc. revenue of about $3.0M for fiscal 2026, with EPS near $-3.47. The estimate reflects 4 contributing analysts.
INTS Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Novel intratumoral drug delivery technology.
- Collaboration agreements with major pharmaceutical companies.
- Phase 2 clinical trials underway for INT230-6.
- Focus on difficult-to-treat solid tumors.
Bear Case
- Limited financial resources.
- Small team size.
- Reliance on clinical trial success.
- High risk of clinical trial failure.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
INTS Latest News
No recent news available for INTS.
INTS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INTS.
Price Targets
Wall Street price target analysis for INTS.
INTS MoonshotScore
What does this score mean?
The MoonshotScore rates INTS 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Lewis H. Bender
CEO
Lewis H. Bender serves as the CEO of Intensity Therapeutics, bringing extensive experience in the biotechnology and pharmaceutical industries. His background includes leadership roles in various companies focused on drug development and commercialization. He has a proven track record in strategic planning, fundraising, and business development. Bender's expertise spans across multiple therapeutic areas, including oncology, and he has been instrumental in guiding Intensity Therapeutics' clinical development programs.
Track Record: Under Lewis H. Bender's leadership, Intensity Therapeutics has advanced INT230-6 into Phase 2 clinical trials and secured collaboration agreements with Merck and Bristol-Myers Squibb. These partnerships represent significant milestones for the company and validate the potential of its technology platform. Bender has also overseen the company's fundraising efforts and strategic planning initiatives.
INTS Healthcare Stock FAQ
What does the AI Score mean for INTS?
INTS holds an AI Score of 27/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cancer drugs for solid tumors. Their lead product candidate, INT230-6, is currently in Phase 2 clinical …
What does Intensity Therapeutics, Inc. do?
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel cancer therapeutics. Their primary product candidate, INT230-6, is designed for direct intratumoral injection to treat solid tumors. The company's approach aims to induce tumor cell death and stimulate an anti-tumor immune response.
What do analysts say about INTS stock?
Analyst coverage of Intensity Therapeutics is limited, reflecting its small market capitalization and early stage of development. However, the company's collaborations with Merck and Bristol-Myers Squibb are viewed positively, suggesting potential for future growth. Investors should carefully consider the risks associated with clinical-stage biotechnology companies, including the possibility of clinical trial failures and regulatory hurdles.
What are the main risks for INTS?
The primary risks for Intensity Therapeutics include the potential for clinical trial failures, regulatory delays, and competition from other cancer drug developers. The company's limited financial resources also pose a risk, as it relies on external funding to support its research and development activities.
How does Intensity Therapeutics, Inc. navigate regulatory approval processes?
Intensity Therapeutics navigates regulatory approval processes primarily through adherence to FDA guidelines and close collaboration with regulatory agencies. The company meticulously designs and executes its clinical trials to meet the requirements for safety and efficacy data. They maintain open communication with the FDA to address any concerns and ensure compliance with all applicable regulations.
How does Intensity Therapeutics, Inc. manage patent expiration risks?
Intensity Therapeutics manages patent expiration risks by actively seeking patent protection for its key technologies and drug candidates, including INT230-6. The company strategically files patent applications to cover various aspects of its inventions, such as composition of matter, methods of use, and formulations.
What are the key factors to evaluate for INTS?
Intensity Therapeutics, Inc. (INTS) holds an AI score of 27/100 (low). Intensity Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. Not financial advice.
How frequently does INTS data refresh on this page?
INTS's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven INTS's recent stock price performance?
Intensity Therapeutics, Inc. (INTS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel intratumoral drug delivery technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- The biotechnology industry is inherently risky, and investment decisions should be made with caution.